These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25478025)

  • 1. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
    Rafii MS
    Alzheimers Res Ther; 2014; 6(5-8):60. PubMed ID: 25478025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Alzheimer's disease therapeutics.
    Rafii MS
    J Alzheimers Dis; 2014; 42 Suppl 4():S545-9. PubMed ID: 25079804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Biomarkers for Alzheimer's Disease in Down Syndrome.
    Lee NC; Chien YH; Hwu WL
    Neurol Ther; 2017 Jul; 6(Suppl 1):69-81. PubMed ID: 28733957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.
    Strydom A; Coppus A; Blesa R; Danek A; Fortea J; Hardy J; Levin J; Nuebling G; Rebillat AS; Ritchie C; van Duijn C; Zaman S; Zetterberg H
    Alzheimers Dement (N Y); 2018; 4():703-713. PubMed ID: 30581976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rodent Modeling of Alzheimer's Disease in Down Syndrome:
    Farrell C; Mumford P; Wiseman FK
    Front Neurosci; 2022; 16():909669. PubMed ID: 35747206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.
    Wilcock DM; Hurban J; Helman AM; Sudduth TL; McCarty KL; Beckett TL; Ferrell JC; Murphy MP; Abner EL; Schmitt FA; Head E
    Neurobiol Aging; 2015 Sep; 36(9):2468-74. PubMed ID: 26103884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP.
    Nizetic D; Chen CL; Hong W; Koo EH
    Front Behav Neurosci; 2015; 9():299. PubMed ID: 26648852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
    Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome.
    Lee JH; Chulikavit M; Pang D; Zigman WB; Silverman W; Schupf N
    Neurosci Lett; 2007 Sep; 425(2):105-9. PubMed ID: 17826910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of risk factors of Alzheimer's disease in the Down syndrome.
    Folin M; Baiguera S; Conconi MT; Pati T; Grandi C; Parnigotto PP; Nussdorfer GG
    Int J Mol Med; 2003 Feb; 11(2):267-70. PubMed ID: 12525890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach.
    Sukreet S; Rafii MS; Rissman RA
    Alzheimers Dement (Amst); 2024; 16(2):e12580. PubMed ID: 38623383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Memory and Cognition in Individuals with Down Syndrome.
    Rafii MS
    CNS Drugs; 2016 Jul; 30(7):567-73. PubMed ID: 27272473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
    Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
    Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
    Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
    J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease and down syndrome: from meiosis to dementia.
    Petronis A
    Exp Neurol; 1999 Aug; 158(2):403-13. PubMed ID: 10415146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Con: are we ready to translate Alzheimer's disease-modifying therapies to people with down syndrome?
    Head E; Schmitt FA
    Alzheimers Res Ther; 2014; 6(5-8):61. PubMed ID: 25478026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell models for Down syndrome-Alzheimer's disease research.
    Wu Y; West NR; Bhattacharyya A; Wiseman FK
    Neuronal Signal; 2022 Apr; 6(1):NS20210054. PubMed ID: 35449591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-Amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer's disease, Parkinson's disease, and Down syndrome.
    Crino PB; Martin JA; Hill WD; Greenberg B; Lee VM; Trojanowski JQ
    Ann Otol Rhinol Laryngol; 1995 Aug; 104(8):655-61. PubMed ID: 7639477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
    Sun X; He G; Song W
    FASEB J; 2006 Jul; 20(9):1369-76. PubMed ID: 16816112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.